Olorinab (APD371)

About the Investigational Medication

Olorinab (APD371) is being evaluated in the clinical study to treat visceral pain, specifically pain associated with Crohn’s disease (CD). Olorinab is considered investigational because it is not approved by health authorities, including the U.S. Food and Drug Administration (FDA), for the treatment of pain associated with CD.

About Visceral Pain

Visceral pain is defined as pain that originates within muscle, pleura, connective tissue, nervous system or solid organs within the abdomen or peritoneum. It is distinct from somatic or neuropathic pain, and is perceived as stretching, pulling and distention, rather than by cutting, crushing, or burning more commonly associated with neuropathic pain. Visceral pain is one of the most common types of pain. For example, abdominal pain affects approximately 20% of the general population. Visceral pain may be caused by a diverse set of organic causes, such as inflammation (e.g., Inflammatory bowel diseases or IBD (including Crohn’s disease (CD) and UC), pancreatitis, prostatitis, and vaginitis), obstruction (e.g., bowel obstruction, and nephrolithiasis), ischemia, and malignancy, among others. Visceral pain may also be caused by functional disorders such as interstitial cystitis, dyspepsia, irritable bowel syndrome (IBS), and vulvodynia.

A specific type of visceral pain, pain associated with CD, affects a significant portion of patients with underlying CD. CD affects approximately 780,000 patients in the U.S., and 20% of patients suffer from residual pain even while in remission.

Ph 2b Planning is ongoing.  

To Learn More, visit clinicaltrials.gov.